Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness (how well a drug works)
of Carbidopa/levodopa (Sinemet) in individuals with Angelman syndrome. Sinemet is a
medication that helps to raise dopamine levels (a chemical that signals nerve cells) in the
brain and central nervous system. There is evidence that dopamine concentrations may be
abnormal in patients with Angelman syndrome. This study is investigating whether Sinemet
helps motor control, intellectual function and the achievement of developmental milestones in
people with Angelman syndrome
Phase:
N/A
Details
Lead Sponsor:
Bennett Lavenstein
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa